Case Control Study
Copyright ©The Author(s) 2020.
World J Gastroenterol. Aug 21, 2020; 26(31): 4607-4623
Published online Aug 21, 2020. doi: 10.3748/wjg.v26.i31.4607
Table 1 General characteristics of patients and healthy controls
CharacteristicsC (n = 30)Y (n = 29)N (n = 31)P value
Sex (Male/Female)25/521/825/60.565
Age (yr)52.93 ± 11.0156.63 ± 9.1551.23 ± 11.790.148
PathogensHBV2524/0.720
HCV12
HBV + HCV10
None33
AFP (ng/mL)> 200110/0.000
50-19941
< 501528
ALT (U/L)162.32 ± 201.0691.02 ± 156.3920.34 ± 8.430.000
AST (U/L)146.35 ± 112.70114.49 ± 191.6721.59 ± 4.510.012
TBIL (μmol/L)39.21 ± 68.3840.87 ± 42.419.66 ± 2.660.015
DBIL (μmol/L)17.91 ± 34.4317.90 ± 23.034.49 ± 1.380.044
TP (g/L)62.42 ± 10.9574.14 ± 8.0572.31 ± 3.960.000
ALB (g/L)33.51 ± 6.3037.65 ± 7.6445.36 ± 2.620.000
Child-Pugh score (A/B)18/1215/14/0.353
Table 2 Significantly altered metabolites
Retention timem/zMetabolitesAdductionAdduct massDelta ppmCoefficient of variation (%)Comparison
3.52C vs NY vs NC vs Y
9.57166.0862PhenylalanineM + H166.08631.008.36DUNS
3.49118.0864ValineM + H118.08631.006.76DNSNS
6.63132.1019LeucineM + H132.10190.003.34NSUNS
3.58116.0708ProlineM + H116.07061.0014.23DDD
5.42182.0811TyrosineM + H182.08120.006.12NSUNS
6.05132.1019IsoleucineM + H132.10190.003.37NSUD
4.89150.0583MethionineM + H150.05830.009.28NSUNS
3.16156.0766HistidineM + H156.07681.0010.83DUD
3.44148.0602Glutamic acidM + H148.06042.006.38UDU
3.32106.0502SerineM + H106.04993.002.59DUD
3.38147.0762GlutamineM + H147.07641.0011.41NSDD
3.4490.0554AlanineM + H90.05505.0012.28DDNS
5.43165.0546Hydroxycinnamic acidM + H165.05460.0016.17DNSD
5.43123.0442Benzoic acidM + H123.04411.0010.11DUNS
9.57149.0596Cinnamic acidM + H149.05971.0012.29DUNS
24.40190.0497Kynurenic acidM + H190.04991.006.51DDU
26.39169.0495Vanillic acidM + H169.04950.003.41DDU
13.83239.0912Trimethoxycinnamic acidM + H239.09141.005.08DUNS
18.85279.2318Linolenic acidM + H279.23190.0011.26DNSD
3.10130.0862Pipecolinic acidM + H130.08630.0010.58DUNS
29.42494.3235LysoPC 16:1M + H494.32411.004.32NSDD
22.87542.3234LysoPC 20:5M + H542.32411.003.09NSDNS
17.33548.3705LysoPC 20:2M + H548.37111.002.31DDNS
21.65550.3857LysoPC 20:1M + H550.38672.005.58DDNS
23.13468.3078LysoPC 14:0M + H468.30851.006.27DDD
19.25478.2926LysoPE 20:1M + H478.29280.008.72DNSNS
17.58181.0857PropylparabenM + H181.08591.006.39DNSNS
5.42136.0756AcetylarylamineM + H136.07570.002.59DUD
18.20127.0390TrihydroxybenzeneM + H127.03900.0013.83DUD
22.22191.1428DamascenoneM + H191.14301.0010.02UDNS
10.70181.0718MyoinositolM + H181.07076.008.55DNSNS
4.88137.0457HydroxypurineM + H137.04581.009.74UDU
3.48114.0664CreatinineM + H114.06622.007.83DNSNS
3.8272.0815PyrrolidineM + H72.080810.002.09UUNS
11.71195.0875Methyl lucopyranosideM + H195.08636.0012.43DNSNS
Table 3 The efficiency of the diagnostic model
ModelAccuracy (%)Sensitivity (%)Specificity (%)Positive predictive valueNegative predictive valueROC-AUC (95%CI)P value
Training setLDA95.00100.0090.000.911.000.90 (0.81-0.99)< 0.05
AFP65.0030.00100.001.000.590.69 (0.52-0.86)
Validation setLDA78.95100.0060.000.691.000.84 (0.67-1.00)< 0.05
AFP68.4240.00100.001.000.600.68 (0.41-0.94)